ClinicalTrials.gg
CompletedNCT00654446Updated Mar 16, 2009

IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin

A Phase 3 interventional study of Rosuvastatin and Simvastatin in Fredrickson Type IIa & Type IIb Dyslipidaemia, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
442
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing rosuvastatin in Dyslipidemias — 2 open to participants now, 2 under way, none of them phase 3. rosuvastatin · Dyslipidemias.

Enrollment
8th of 42
442 · median 128
Started
2002
with 4 others
Phase 3
14 of 42
none open now
Registered
8th of 42
by date
Lead sponsor
10 of 42
AstraZeneca

Among the 42 studies testing rosuvastatin in Dyslipidemias, this one is the 8th largest by enrollment, is one of 5 that started in 2002, is one of 14 in phase 3, and was the 8th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

2 of the 42 studies testing rosuvastatin in Dyslipidemias are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing rosuvastatin in Dyslipidemias, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effects on the kidney of rosuvastatin and simvastatin in subjects with Fredrickson Type IIa \& Type IIb Dyslipidaemia

03

Conditions studied

  • Fredrickson Type IIa & Type IIb Dyslipidaemia

Browse trials for

Keywords

  • Cholesterol
  • low density lipoproteins
  • dyslipidaemia
  • Rosuvastatin
  • Crestor
  • Simvastatin
  • Zocor
  • Renal
  • kidney
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fasting low density lipoprotein level as defined by the protocol.
  • Fasting triglyceride level as defined by the protocol.

Exclusion criteria

Exclusion Criteria:

  • The use of lipid lowering drugs or dietary supplements after Visit 1.
  • Active arterial disease eg Unstable angina, or recent arterial surgery
  • Blood creatine levels above the limits defined in the protocol or +4 proteinuria during dietary lead in period.
  • Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
442 participants

Study arms

  • Experimental
    1

    Rosuvastatin

    Drug: Rosuvastatin

  • Active comparator
    2

    Simvastatin

    Drug: Simvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Development of Proteinuria

    Time frame: 2 weekly

Secondary outcomes

  1. Renal effects of rosuvastatin and simvastatin

    Time frame: 2 weekly

  2. Low density lipoproteins cholesterol levels

    Time frame: 2 weekly

  3. Safety: adverse events & abnormal laboratory markers

    Time frame: 2 weekly

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2008
First posted
Apr 8, 2008
Start
Sep 2002
CompletionActual
Apr 2004
Last update
Mar 16, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00654446
Lead sponsor
AstraZeneca
First posted
Apr 8, 2008
Start date
Sep 2002
Completion
Apr 2004
Last update
Mar 16, 2009

Study contacts

Evan Stein
principal investigator · Metabolic & Athersclerotic research centre, Cincinatti, USA
Russell Esterline
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion